Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov 27;515(7528):572-6.
doi: 10.1038/nature14001.

Predicting Immunogenic Tumour Mutations by Combining Mass Spectrometry and Exome Sequencing

Affiliations

Predicting Immunogenic Tumour Mutations by Combining Mass Spectrometry and Exome Sequencing

Mahesh Yadav et al. Nature. .

Abstract

Human tumours typically harbour a remarkable number of somatic mutations. If presented on major histocompatibility complex class I molecules (MHCI), peptides containing these mutations could potentially be immunogenic as they should be recognized as 'non-self' neo-antigens by the adaptive immune system. Recent work has confirmed that mutant peptides can serve as T-cell epitopes. However, few mutant epitopes have been described because their discovery required the laborious screening of patient tumour-infiltrating lymphocytes for their ability to recognize antigen libraries constructed following tumour exome sequencing. We sought to simplify the discovery of immunogenic mutant peptides by characterizing their general properties. We developed an approach that combines whole-exome and transcriptome sequencing analysis with mass spectrometry to identify neo-epitopes in two widely used murine tumour models. Of the >1,300 amino acid changes identified, ∼13% were predicted to bind MHCI, a small fraction of which were confirmed by mass spectrometry. The peptides were then structurally modelled bound to MHCI. Mutations that were solvent-exposed and therefore accessible to T-cell antigen receptors were predicted to be immunogenic. Vaccination of mice confirmed the approach, with each predicted immunogenic peptide yielding therapeutically active T-cell responses. The predictions also enabled the generation of peptide-MHCI dextramers that could be used to monitor the kinetics and distribution of the anti-tumour T-cell response before and after vaccination. These findings indicate that a suitable prediction algorithm may provide an approach for the pharmacodynamic monitoring of T-cell responses as well as for the development of personalized vaccines in cancer patients.

Comment in

Similar articles

  • Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
    Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö, Sahin U. Kreiter S, et al. Nature. 2015 Apr 30;520(7549):692-6. doi: 10.1038/nature14426. Epub 2015 Apr 22. Nature. 2015. PMID: 25901682 Free PMC article.
  • Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens.
    Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N, Schachter J, Rosenberg SA, Besser MJ, Admon A, Samuels Y. Kalaora S, et al. Oncotarget. 2016 Feb 2;7(5):5110-7. doi: 10.18632/oncotarget.6960. Oncotarget. 2016. PMID: 26819371 Free PMC article.
  • Immunotherapy: personalizing tumour vaccines.
    Killock D. Killock D. Nat Rev Clin Oncol. 2015 Feb;12(2):64. doi: 10.1038/nrclinonc.2014.220. Epub 2014 Dec 16. Nat Rev Clin Oncol. 2015. PMID: 25511189 No abstract available.
  • [Neoantigens and Whole-Exome Sequencing].
    Karasaki T, Nakajima J, Kakimi K. Karasaki T, et al. Gan To Kagaku Ryoho. 2016 Jul;43(7):791-7. Gan To Kagaku Ryoho. 2016. PMID: 27431622 Review. Japanese.
  • [MHC tetramers: tracking specific immunity].
    Kosor E, Gagro A, Drazenović V, Kuzman I, Jeren T, Rakusić S, Rabatić S, Markotić A, Gotovac K, Sabioncello A, Cecuk E, Kerhin-Brkljacić V, Gjenero-Margan I, Kaić B, Mlinarić-Galinović G, Kastelan A, Dekaris D. Kosor E, et al. Acta Med Croatica. 2003;57(4):255-9. Acta Med Croatica. 2003. PMID: 14639858 Review. Croatian.
See all similar articles

Cited by 317 articles

See all "Cited by" articles

References

    1. Biochem Soc Trans. 2007 Feb;35(Pt 1):12-7 - PubMed
    1. Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W509-12 - PubMed
    1. J Immunol. 2002 Sep 15;169(6):3137-45 - PubMed
    1. J Exp Med. 2008 Mar 17;205(3):595-610 - PubMed
    1. Blood. 2012 Jun 28;119(26):e181-91 - PubMed

LinkOut - more resources

Feedback